Evaluation of circulating kidney injury marker-1 (KIM-1) as a prognostic and predictive biomarker in advanced renal cell carcinoma (aRCC): Post-hoc analysis of CheckMate 214.
Related Presenters
Medical Oncology
Dr. Xu received his MD from Harvard Medical School in 2014. He completed residency training in internal medicine at Beth Israel Deaconess Medical Center, followed by fellowship training in hematology and medical oncology also at Beth Israel ...
Related Videos
